NCT07425535 Optic Nerve Head Strain in Non-glaucoma Subjects
| NCT ID | NCT07425535 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | Johns Hopkins University |
| Condition | Glaucoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2026-06-24 |
| Primary Completion | 2028-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 30 participants in total. It began in 2026-06-24 with a primary completion date of 2028-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Persons who do not have glaucoma will have pictures taken of the optic nerve with a standard camera before and 2 weeks after starting to take a daily glaucoma eye drop to lower eye pressure. These data will be used to compare to the same procedure performed with glaucoma patients to study how glaucoma injures the eye.
Eligibility Criteria
Inclusion Criteria: * Adults who have no history of OAG * Have an ocular examination by a glaucoma specialist with no indications of OAG * Have normal optical coherence tomography findings in the retinal nerve fiber layer. * Over age 30 will be included from * Both sexes * All ethnic groups. * Optic neuropathy. * Both suspects and those with glaucoma damage will be included. * When both eyes meet inclusion and exclusion criteria, both eyes will be included in the study and statistical methods will be used to account for correlations between eyes within the same individual. Exclusion Criteria: * in whom sitting in an upright position is impossible due to physical disability * with ocular media opacity, corneal scarring, cataract or vitreous hemorrhage, that does not allow adequate imaging resolution. * in whom keeping the eyes open during the imaging procedure is not possible or uncomfortable. * who cannot perform home tonometry accurately at certification * who do not have reliable clinical Optical Coherence Tomography (OCT) testing. * with any form of glaucoma * with high myopia defined as refractive error \> -8 * with past keratorefractive surgery, corneal dystrophy, or corneal ectasia that would make self-tonometry measurements difficult to interpret * inability to understand English or with a language or hearing impairment
Contact & Investigator
Harry Quigley, MD
PRINCIPAL INVESTIGATOR
Johns Hopkins University
Frequently Asked Questions
Who can join the NCT07425535 clinical trial?
This trial is open to participants of all sexes, aged 30 Years or older, up to 90 Years, studying Glaucoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07425535 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07425535 currently recruiting?
Yes, NCT07425535 is actively recruiting participants. Contact the research team at hquigley@jhmi.edu for enrollment information.
Where is the NCT07425535 trial being conducted?
This trial is being conducted at Baltimore, United States.
Who is sponsoring the NCT07425535 clinical trial?
NCT07425535 is sponsored by Johns Hopkins University. The principal investigator is Harry Quigley, MD at Johns Hopkins University. The trial plans to enroll 30 participants.